Pharma executives predict increase in patent deal-making following US tax reform 12 Jan 18
A number of leading pharmaceuticals executives have said that recent US tax reforms will create a more conducive environment for patent transactions. Corroborating forecasts made by leading industry analysts suggest that 2018 will see a significant surge in this kind of deal-making in the life sciences sector.
Want to read more?
Register to access two of our subscriber-only articles per month
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts
What our customers are saying
IAM is the only publication that places a business focus on intellectual property. Readers are given real insight into, and guidance on, managing intellectual property as a true business asset.
Reed Smith LLP
Subscribe to receive access to the full range of premium business intelligence, insights and analysis, as well as our IP directories, guides and daily news.
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email